Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Stimulant or Tryptamine or [[:Category:Overactive_bladder_medications|Overactive bladder medication]]

Use the filters below to narrow your results.

generic:
brand:
None (67) · Benzedrex (1) · Ditropan, Ditropan XL, Oxytrol (transdermal), Gelnique (gel) (1) · Myrbetriq (1) · Vesicare (1)
classes: (Click arrow to add another value)
mechanism:
5-HT2A agonist (15) · Monoamine releasing agent (8) · Dopamine/norepinephrine reuptake inhibitor (5) · None (2) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · Norepinephrine–dopamine reuptake inhibitor (2)
uses:
None (68) · '"`UNIQ--vote-000006DE-QINU`"', '"`UNIQ--vote-000006DF-QINU`"', '"`UNIQ--vote-000006E0-QINU`"' (1) · '"`UNIQ--vote-00000C4C-QINU`"', '"`UNIQ--vote-00000C4D-QINU`"' (1) · '"`UNIQ--vote-00000DFC-QINU`"', '"`UNIQ--vote-00000DFD-QINU`"' (1)
starting dose:
None (68) · 25 mg PO once daily; titrate to 50 mg after 4-8 weeks if needed (1) · 5 mg PO once daily; titrate to 10 mg after 2 weeks if needed (1) · IR 5 mg PO BID-TID; ER 5-10 mg PO daily, titrate; transdermal patch 3.9 mg/d twice weekly (OTC) (1)
preparations:
None (68) · 25, 50 mg ER tablets; 8 mg/mL granules for oral suspension (Myrbetriq Granules, pediatric) (1) · 5 mg IR tablets; 5, 10, 15 mg ER tablets; 5 mg/5 mL syrup; 3.9 mg/24 h transdermal patch (Oxytrol); 10% topical gel (1) · 5, 10 mg tablets (1)
fda max:
None (68) · 10 mg/d (5 mg if severe renal or moderate hepatic impairment, or strong CYP3A4 inhibitors) (1) · 30 mg/d (XL) typical (1) · 50 mg/d (1)
routes:
None (68) · intravesical (1) · Oral (3) · topical gel (1) · transdermal (1)
onset:
None (68) · 30-60 minutes (PO) (1) · Symptom improvement within 1-2 weeks (1) · Symptom improvement within weeks (1)
duration:
None (68) · 24 hours (2) · IR: 6-10 hours; ER: 24 hours (1)
halflife:
None (68) · 2-3 hours (parent and active N-desethyl metabolite)'"`UNIQ--ref-000006E1-QINU`"' (1) · ~45-68 hours'"`UNIQ--ref-00000DFE-QINU`"' (1) · ~50 hours'"`UNIQ--ref-00000C4E-QINU`"' (1)
bioavailability:
None (68) · 25 mg: ~29%; 50 mg: ~35%; food reduces absorption'"`UNIQ--ref-00000C4F-QINU`"' (1) · ~6% IR oral (substantial first-pass to active N-desethyl metabolite, which contributes most of the antimuscarinic adverse effects); transdermal bypasses first-pass and is better tolerated'"`UNIQ--ref-000006E2-QINU`"' (1) · ~90% (oral)'"`UNIQ--ref-00000DFF-QINU`"' (1)
pregnancy:
None (68) · Limited data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (3)
legal:
None (68) · OTC (transdermal patch in women) and [[USLegal:Prescription only|Rx-only]] (other forms) in US (1) · [[USLegal:Prescription only|Rx-only]] in US (2)

Showing below up to 72 results in range #1 to #72.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"